The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Open accessPublished version of a preprint
Abstract
The CRISPR-Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR-Cas9 system to therapeutically correct human genetic diseases 1-6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes 5,7. Given that these two bacterial species infect the human population at high frequencies 8,9, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells in 67% of donors, which demonstrates a high prevalence of antigen-specific T cells against both orthologs. We confirmed that these T cells were Cas9-specific by demonstrating a Cas9-specific cytokine response following isolation, expansion, and antigen restimulation. Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR-Cas9 system moves toward clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, long-term expression of genome editing molecules may expose patients to undesired off-target editing or immune reactions 66,67 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-existing Cas9 antibodies and reactive T-cells have been detected in humans exposed to pathogenic bacteria harboring CRISPR systems, although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other factors affecting clinical applications of genome editing include the immunogenicity of bacterially-derived editing proteins, the potential for pre-existing antibodies against CRISPR components to cause inflammation and the unknown long-term safety and stability of genome editing outcomes.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another consideration for CRISPR/Cas9-based systems for retinal gene editing is the potential for a heightened adaptive immune response given the bacterial origin of the Cas9 enzyme and high prevalence of pre-existing immunity (Charlesworth et al., 2019).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Charlesworth et al., 2019
In the citing paper
“A study involving 125 healthy adult human blood donors in the USA with a median age of 43 reported pre-existing anti-SaCas9 antibodies and anti-SpCas9 antibodies in 78% and 58% of the total samples, respectively.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“Among the tested donors, 78% had SaCas9-specific T-cells and 67% were positive for SpCas9-specific T-cells.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“While there are discrepancies regarding the exact prevalence of these antibodies in humans, a majority of the general population may exhibit preexisting α-Cas93.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“Furthermore, a high prevalence of preexisting cellular immunity against Cas9 (Cas9-reactive T-cells) has also been identified2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“multiple groups have reported high frequencies (>60% of patients) of Cas9 reactive T-cells in humans2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“This may explain the lower raw ELISA A450 values we observed compared with previous work (Table 1)3.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“CRISPR-Cas9 is a promising therapeutic tool that allows genetic target-specific cleavage and editing (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
In the citing paper
“One concern is that the prevalence of anti-SaCas9 antibodies and T-cell in humans are reported to be 78% (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,018
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Pukelsheim, F. (1994) · The American Statistician · doi:10.1080/00031305.1994.10476030 · Cited by 1,072
Cited by
Sorted by citations
Items 501–600 of 1,000
Protection is not always a good thing: The immune system’s impact on gene therapy
de Freitas, M. V., Frâncio, L., Haleva, L., & Matte, Ú. D. S. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2022-0046 · Cited by 18
Bairqdar, A., Karitskaya, P. E., & Stepanov, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413321 · Cited by 17
Rewriting CFTR to cure cystic fibrosis
Maule, G., Ensinck, M. M., Bulcaen, M., & Carlon, M. S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.018 · Cited by 17
Therapeutics Development for Alagille Syndrome
Sanchez, P. R., Farkhondeh, A., Pavlinov, I., Baumgaertel, K., Rodems, S. M., & Zheng, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.704586 · Cited by 19
Huang, L., Liao, Z., Liu, Z., Chen, Y., Huang, T., & Xiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900825 · Cited by 16
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/3nwzd · Cited by 22
Emerging Perspectives on Prime Editor Delivery to the Brain
BenDavid, E., Ramezanian, S., Lu, Y., Rousseau, J., Schroeder, A., Lavertu, M., & Tremblay, J. P. (2024) · Pharmaceuticals · doi:10.3390/ph17060763 · Cited by 16
Gene Editing to Tackle Facioscapulohumeral Muscular Dystrophy
Mariot, V., & Dumonceaux, J. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.937879 · Cited by 16
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy
Padmaswari, M. H., Agrawal, S., Jia, M. S., Ivy, A., Maxenberger, D. A., Burcham, L. A., & Nelson, C. E. (2023) · Biophysics Reviews · doi:10.1063/5.0131452 · Cited by 18
The Dawn of In Vivo Gene Editing Era: A Revolution in the Making
Niazi, S. K. (2023) · Biologics · doi:10.3390/biologics3040014 · Cited by 17
Enhancing cell‐based therapies with synthetic gene circuits responsive to molecular stimuli
Galvan, S., Teixeira, A. P., & Fussenegger, M. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28770 · Cited by 16
Assessment of CRISPRa-mediated gdnf overexpression in an In vitro Parkinson’s disease model
Guzmán-Sastoque, P., Sotelo, S., Esmeral, N. P., Albarracín, S. L., Sutachan, J. J., Reyes, L. H., Muñoz-Camargo, C., Cruz, J. C., & Bloch, N. I. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1420183 · Cited by 15
Genetic Modification of Animals: Scientific and Ethical Issues
Bailey, J. (2019) · BRILL eBooks · doi:10.1163/9789004391192_020 · Cited by 16
Aspects of Gene Therapy Products Using Current Genome-Editing Technology in Japan
Yamaguchi, T., Uchida, E., Okada, T., Ozawa, K., Onodera, M., Kume, A., Shimada, T., Takahashi, S., Tani, K., Nasu, Y., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.156 · Cited by 16
CRISPR Screens to Identify Regulators of Tumor Immunity
LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 16
Wasala, N. B., Hakim, C. H., Chen, S., Yang, N. N., & Duan, D. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.243 · Cited by 15
CRISPR Takes the Front Seat in CART-Cell Development
Manriquez-Roman, C., Siegler, E. L., & Kenderian, S. S. (2021) · BioDrugs · doi:10.1007/s40259-021-00473-y · Cited by 15
Simons, E. J., & Trapani, I. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.126 · Cited by 14
Advances in Therapeutic Applications of CRISPR Genome Editing for Spinal Pain Management
Kang, C. Y., Been, K. W., Kang, M. R., Choi, M. S., Kang, R. H., Hur, J. W., & Hur, J. K. (2025) · Neurospine · doi:10.14245/ns.2550462.231 · Cited by 15
Xu, L., Lahiri, P., Skowronski, J., Bhatia, N., Lattanzi, A., & Porteus, M. H. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.009 · Cited by 16
Self-citationMurugesan, R., Karuppusamy, K. V., Marepally, S. K., & Thangavel, S. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1148693 · Cited by 15
LaFleur, M. W., Lemmen, A. M., Streeter, I. S. L., Nguyen, T. H., Milling, L. E., Derosia, N. M., Hoffman, Z. M., Gillis, J. E., Tjokrosurjo, Q., Markson, S. C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01689-6 · Cited by 14
CRISPR-Cas9 in basic and translational aspects of cancer therapy
Salavatipour, M. S., Poursalehi, Z., Rouzbahani, N. H., Mohammadyar, S., & Vasei, M. (2024) · Bioimpacts · doi:10.34172/bi.2024.30087 · Cited by 14
Kaur, G., Arora, J., Sodhi, A. S., Bhatia, S., & Batra, N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01301-8 · Cited by 14
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design
Gaimari, A., Lucia, A. D., Nicolini, F., Mazzotti, L., Maltoni, R., Rughi, G., Zurlo, M., Marchesini, M., Juan, M., Parras, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212201 · Cited by 16
Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 15
Characterization of diverse Cas9 orthologs for genome and epigenome editing
Butterfield, G. L., Rohm, D., Roberts, A., Nethery, M. A., Rizzo, A. J., Morone, D. J., Garnier, L., Iglesias, N., Barrangou, R., & Gersbach, C. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417674122 · Cited by 14
Wong, P. K., Cheah, F., Syafruddin, S. E., Mohtar, M. A., Azmi, N., Ng, P. Y., & Chua, E. W. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.592571 · Cited by 14
Bond, S. T., Zhuang, A., Yang, C., Gould, E. A. M., Sikora, T., Liu, Y., Fu, Y., Watt, K. I., Tan, Y., Kiriazis, H., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101292 · Cited by 14
Hegeman, C. V., Elsharkasy, O. M., Driedonks, T. A. P., Friesen, K., Vader, P., & de Jong, O. G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113853 · Cited by 13
Kozani, P. S., & Kozani, P. S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07183-x · Cited by 13
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 13
Chang, S.-H., & Park, C. (2023) · Immune Network · doi:10.4110/in.2023.23.e44 · Cited by 13
CRISPR/Cas9: an overview of recent developments and applications in cancer research
Devi, S. N., Rana, R., Malik, P., & Ganguly, N. K. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001081 · Cited by 14
Elasbali, A. M., Al‐Soud, W. A., Anwar, S., Alhassan, H. H., Adnan, M., & Hassan, M. I. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130544 · Cited by 14
Challenges and progress related to gene editing in rare skin diseases
Hofbauer, J. P., Guttmann‐Gruber, C., Wally, V., Sharma, A. K., Gratz, I. K., & Koller, U. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115294 · Cited by 13
Gene editing therapy for cardiovascular diseases
Wu, X., Yang, J., Zhang, J., & Song, Y. (2024) · MedComm · doi:10.1002/mco2.639 · Cited by 14
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 13
Beraza-Millor, M., Rodríguez-Castejón, J., del Pozo‐Rodríguez, A., Rodríguez‐Gascón, A., & Solinís, M. Á. (2024) · BioDrugs · doi:10.1007/s40259-024-00674-1 · Cited by 13
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13
In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?
Rhee, J., & Wu, J. C. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.38 · Cited by 13
Jamehdor, S., Pajouhanfar, S., Saba, S., Uzan, G., Teimoori, A., & Naserian, S. (2022) · Cells · doi:10.3390/cells11060999 · Cited by 13
Gene Editing and Rett Syndrome: Does It Make the Cut?
Coorey, B., Haase, F., Ellaway, C., Clarke, A. J., Lisowski, L., & Gold, W. A. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0020 · Cited by 13
Salman, M., Verma, A., Singh, V. K., Jaffet, J., Chaurasia, S., Sahel, D. K., Ramappa, M., & Singh, V. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000443 · Cited by 13
Arango, D., Cifuentes, J., Puentes, P. R., Beltran, T., Bittar, A., Ocasión, C., Muñoz-Camargo, C., Bloch, N. I., Reyes, L. H., & Cruz, J. C. (2023) · Nanomaterials · doi:10.3390/nano13111782 · Cited by 13
Emerging approaches to induce immune tolerance to therapeutic proteins
Noel, J. C., Lagassé, D., Golding, B., & Sauna, Z. E. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.10.002 · Cited by 13
Nieto-Romero, V., García-Torralba, A., Molinos-Vicente, A., Moya, F., Rodríguez, S., García‐Escudero, R., SALIDO, E. C., Segovia, J. C., & Garcı́a-Bravo, M. (2024) · iScience · doi:10.1016/j.isci.2024.109530 · Cited by 13
Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies
Mehravar, M., Roshandel, E., Salimi, M., Chegeni, R., Gholizadeh, M., Mohammadi, M. H., & Hajifathali, A. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.07.003 · Cited by 13
Correction of the aprt Gene Using Repair-Polypurine Reverse Hoogsteen Hairpins in Mammalian Cells
Félix, A. J., Ciudad, C. J., & Noé, V. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.12.015 · Cited by 13
Pulman, J., Botto, C., Malki, H., Ren, D., Oudin, P., De Cian, A., As, M., Izabelle, C., Saubamea, B., Forster, V., et al. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102349 · Cited by 12
Dipalo, L. L., Mikkelsen, J. G., Gijsbers, R., & Carlon, M. S. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.258 · Cited by 12
Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A
Zhao, J.-J., Tian, S.-N., Peng, Z.-Y., Ren, J., Zhang, Y., Li, G., Deng, D.-H., Zhang, J., & Zhang, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114141 · Cited by 11
CRISPR-Based Transcriptional Regulation: Technologies, Applications, and Future Directions
Srinivasa, M. A., & Escobar, M. (2025) · DNA · doi:10.3390/dna5040057 · Cited by 11
Monitoring biological effects of somatic cell genome editing
Freedman, B., Bulte, J. W. M., Conklin, B. R., Judge, L. M., Dwinell, M. R., Geurts, A. M., Sitton, M. J., Mahajan, V., Kiani, S., Gersbach, C. A., et al. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00916-0 · Cited by 13
Zhao, R., Wang, C., 李佳楣, Liao, Y., Huang, C., Hu, T., Zhang, H., & Zhang, W. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00456-x · Cited by 13
The history, use, and challenges of therapeutic somatic cell and germline gene editing
Ryu, J., Adashi, E. Y., & Hennebold, J. D. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.02.040 · Cited by 12
In vivo delivery systems for CRISPR genome editing: Viral and non-viral carriers
Lee, Y., Kim, B., Lee, D., Cheon, S. Y., Lim, S. G., Kim, Y., & Koo, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0228874 · Cited by 13
Machine-Guided Dual-Objective Protein Engineering for Deimmunization and Therapeutic Functions
Wolfsberg, E., Paul, J.-S., Tycko, J., Chen, B., Bassik, M. C., Bintu, L., Alizadeh, A. A., & Gao, X. J. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101299 · Cited by 14
A Molecular Glue Approach to Control the Half-Life of CRISPR-Based Technologies
Sreekanth, V., Jan, M., Zhao, K. T., Lim, D., Siriwongsup, S., Davis, J. R., McConkey, M. E., Kovalcik, V., Barkal, S., Law, B. K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06230 · Cited by 12
A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System
Bellizzi, A., Ahye, N., Jalagadugula, G. S., & Wollebo, H. S. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09878-7 · Cited by 12
Applications of CRISPR for musculoskeletal research
Fitzgerald, J. (2020) · Bone and Joint Research · doi:10.1302/2046-3758.97.bjr-2019-0364.r2 · Cited by 12
CRISPR-Based Editing Techniques for Genetic Manipulation of Primary T Cells
Kotowski, M., & Sharma, S. (2020) · Methods and Protocols · doi:10.3390/mps3040079 · Cited by 14
Zhi, L., Su, X., Yin, M., Zhang, Z., Lü, H., Niu, Z., Guo, C., Zhu, W., & Zhang, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104436 · Cited by 13
Žužić, M., Striebel, J., Pawlick, J. S., Sharma, K., Holz, F. G., & Busskamp, V. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101065 · Cited by 12
How to detect CRISPR with CRISPR – employing SHERLOCK for doping control purposes
Paßreiter, A., Naumann, N., Thomas, A., Grogna, N., Delahaut, P., & Thevis, M. (2022) · The Analyst · doi:10.1039/d2an01318e · Cited by 12
Lamothe, R. C., Storlie, M. D., Espinosa, D. A., Rudlaff, R. M., Browne, P. J., Liu, J., Rivas, A., Devoto, A. E., Oki, J., Khoubyari, A., et al. (2023) · The CRISPR Journal · doi:10.1089/crispr.2022.0089 · Cited by 12
Mojarrad, M., Qomi, S. B., & Asghari, A. (2019) · Advanced Biomedical Research · doi:10.4103/abr.abr_41_19 · Cited by 12
Non-canonicaly recruited TCRαβCD8αα IELs recognize microbial antigens
Wojciech, Ł., Szurek, E. A., Kuczma, M., Cebula, A., Elhefnawy, W. R., Pietrzak, M., Rempała, G. A., & Ignatowicz, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-29073-7 · Cited by 12
Knocking out barriers to engineered cell activity
Hamilton, J. R., & Doudna, J. A. (2020) · Science · doi:10.1126/science.aba9844 · Cited by 12
Gene Editing Applications as Future Cardiovascular Therapies
Tadokoro, T., Olson, E. N., & Liu, N. (2025) · Annual Review of Genetics · doi:10.1146/annurev-genet-011725-094039 · Cited by 11
Marei, H. E. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05590-1 · Cited by 13
Gene Therapy Medicinal Products: Non-clinical Safety Studies
Astapova, O. V., & Berchatova, A. A. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-1-329 · Cited by 11
A critical review on therapeutic approaches of CRISPR-Cas9 in diabetes mellitus
Bora, J., Dey, A., Lyngdoh, A. R., Dhasmana, A., Ranjan, A., Kishore, S., Rustagi, S., Tuli, H. S., Chauhan, A. P. S., Rath, P., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02631-1 · Cited by 14
Plant Breeding Using the CRISPR-Cas9 System for Food Security and Facing Climate Change
Ambika, A., Bhati, S., & Kumar, R. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-9338-3_6 · Cited by 11
Pironon, N., Bourrat, E., Prost‐Squarcioni, C., Chen, M., Woodley, D. T., Titeux, M., & Hovnanian, A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2401781121 · Cited by 12
Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.031 · Cited by 11
Tounekti, O., Prior, S., Wassmer, S., Xu, J., Wong, A., Fang, X., Sonderegger, I., Smeraglia, J., Huleatt, J. W., Loo, L., et al. (2025) · Bioanalysis · doi:10.1080/17576180.2024.2439229 · Cited by 11
Application and prospects of genetic engineering in CAR-NK cell therapy
Hu, C., Lai, W., Tian, B., Xu, X., Xie, S., Zhong, W., Kang, H., Chen, X., Li, H.-L., Xu, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1600411 · Cited by 12
Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus
Maepa, M. B., Jacobs, R., van den Berg, F. T., & Arbuthnot, P. B. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000623 · Cited by 11
Zhang, Y., & Karakikes, I. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.008 · Cited by 13
Patents, ethics, biosafety and regulation using CRISPR technology
Nxumalo, Z., Takundwa, M. M., & Raj, D. B. T. G. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.023 · Cited by 11
Sensing intracellular signatures with synthetic mRNAs
Ono, H., & Saito, H. (2023) · RNA Biology · doi:10.1080/15476286.2023.2244791 · Cited by 11
Gene editing: Towards the third generation of adoptive T-cell transfer therapies
Puig-Saus, C., & Ribas, A. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.001 · Cited by 12
Chakraborty, S. (2019) · F1000Research · doi:10.12688/f1000research.20744.1 · Cited by 12
Tan, R., Du, W., Liu, Y., Cong, X., Bai, M., Jiang, C., Li, Z., Tan, M., Ma, D. K., Huang, Q., et al. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.09.003 · Cited by 11
Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science
Abdeen, A. A., Cosgrove, B. D., Gersbach, C. A., & Saha, K. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-122019-121602 · Cited by 11
Neuronal Cell-type Engineering by Transcriptional Activation
Liu, S., Striebel, J., Pasquini, G., Ng, A. H. M., Khoshakhlagh, P., Church, G. M., & Busskamp, V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.715697 · Cited by 11
CRISPR/Cas-based Human T cell Engineering: Basic Research and Clinical Application
Bernard, B. E., Landmann, E., Jeker, L. T., & Schumann, K. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.03.005 · Cited by 12
RNA base editors: The emerging approach of RNA therapeutics
Song, J., Luo, N., Dong, L., Peng, J., & Yi, C. (2024) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1844 · Cited by 10
Precise Gene Knock‐In Tools with Minimized Risk of DSBs: A Trend for Gene Manipulation
Liu, Y. H., Kong, J., Liu, G., Li, Z., & Xiao, Y. (2024) · Advanced Science · doi:10.1002/advs.202401797 · Cited by 10
Ruan, W., Xu, S., An, Y., Cui, Y., Liu, Y., Wang, Y., Ismail, M., Liu, Y., & Zheng, M. (2024) · Advanced Science · doi:10.1002/advs.202402178 · Cited by 10
Wang, J., Zhang, W., Li, S., Shi, W., Li, B., Zhang, J., Liang, Y., Teng, X., & Zhang, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17920 · Cited by 10
Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy
Ma, J., Mao, L., Yang, L., Xie, Q., Fan, R., Lu, X., Huang, X., Tong, N., & Duan, Z. (2025) · MedComm · doi:10.1002/mco2.70359 · Cited by 11
Genetics Matters: Voyaging from the Past into the Future of Humanity and Sustainability
Cheng, A., Harikrishna, J. A., Redwood, C. S., Lit, L. C., Nath, S. K., & Chua, K. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073976 · Cited by 10
Thomas, S. P., Domm, J. M., van Vloten, J. P., Xu, L., Vadivel, A., Yates, J. G. E., Pei, Y., Ingrao, J. C., van Lieshout, L. P., Jackson, S. R., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.002 · Cited by 10
Nanoparticle-mediated delivery of non-viral gene editing technology to the brain
Williams, L., & Larsen, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102547 · Cited by 10
Temporal restriction of Cas9 expression improves CRISPR-mediated deletion efficacy and fidelity
Weber, J. A., Lang, J. F., Carrell, E. M., Alameh, M., & Davidson, B. L. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102172 · Cited by 10
In Utero Gene Therapy and its Application in Genetic Hearing Loss
Kong, C., Yin, G., Wang, X., & Sun, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400193 · Cited by 10
A comprehensive review on the current status of CRISPR based clinical trials for rare diseases
Badwal, A. K., & Singh, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134097 · Cited by 10
Metadata
- Authors
- Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., Behlke, M. A., Dejene, B., Cieniewicz, B., Romano, R., Lesch, B. J., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford Medicine (US)
- Integrated DNA Technologies (United States) (US)
- Corresponding author
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- ORCID
- Charlesworth, Carsten T.
- Dever, Daniel P.
- Camarena, Joab
- Lemgart, Viktor T.
- Cromer, M. Kyle
- Vakulskas, Christopher A.
- Collingwood, Michael A.
- Zhang, Liyang
- Bode, Nicole M.
- Behlke, Mark A.
- Dejene, Beruh
- Cieniewicz, Brandon
- Romano, Rosa
- Lesch, Benjamin J.
- Gomez-Ospina, Natalia
- Mantri, Sruthi
- Pavel-Dinu, Mara
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- Venue
- Nature Medicine
- Published
- 2019-01-28
- Volume
- 25
- Issue
- 2
- Pages
- 249-254
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7199589
- OpenAlex
- W2949380898
- Cited by
- 1,093
- References
- 48
- Citations by year
- 2026: 130 · 2025: 128 · 2024: 132 · 2023: 111 · 2022: 125 · 2021: 166 · 2020: 131 · 2019: 110
- FWCI
- 44.16
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nd)
- Funders
- Amon G. Carter Foundation
- National Institutes of Health (5r01ai120766-02)
- National Institute of General Medical Sciences (T32GM119995)
- National Institute of Allergy and Infectious Diseases (R01-AI120766)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, SaCas9, SpCas9, Staphylococcus aureus, Streptococcus pyogenes, humoral immune response, cell-mediated immunity, genome editing safety
- MeSH terms
- CRISPR-Associated Protein 9, Adult, Cell Separation, Female, Humans, Male, T-Lymphocytes, Adaptive Immunity, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
